LY 235959

Drug Profile

LY 235959

Latest Information Update: 25 Aug 1998

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eli Lilly
  • Class Anti-ischaemics; Antidementias; Antiepileptic drugs; Antiparkinsonians; Isoquinolines; Neuroprotectants
  • Mechanism of Action Glutamate receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Movement disorders
  • Discontinued Alzheimer's disease

Most Recent Events

  • 25 Aug 1998 No-Development-Reported for Movement disorders in USA (Unknown route)
  • 14 Aug 1996 LY 235959 is being investigated for use in levodopa-induced dyskinesias
  • 14 Aug 1996 Preclinical development for Movement disorders in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top